Case Reports

An extremely indolent T-cell leukemia: an 18-year follow-up


 

T-cell prolymphocytic leukemia (T-PLL) is a rare malignancy that comprises about 2% of all mature lymphoid neoplasms. Patients usually present with prominent peripheral blood lymphocytosis, splenomegaly, hepatomegaly, lymphadenopathy, B symptoms, and occasionally with skin lesions.1 The disease follows an aggressive clinical course with rapid progression and typically has a median survival of less than 1 year. In some cases, the disease is indolent for a period of time before becoming aggressive.2 In 2002, 7 years after initial diagnosis in 1995, the case discussed herein was reported as a rare, indolent form of T-PLL.3 We now present 11 additional years of follow-up of this case, during which time the patient remained asymptomatic with respect to his lymphoid neoplasm.

Click on the PDF icon at the top of this introduction to read the full article.​

Recommended Reading

FDA gives breakthrough status to midostaurin for AML
MDedge Hematology and Oncology
Ponatinib effective in chronic phase CML regardless of baseline mutation status
MDedge Hematology and Oncology
Prognostic value of complete remission with superior platelet counts in acute myeloid leukemia
MDedge Hematology and Oncology
Drug granted breakthrough designation for AML
MDedge Hematology and Oncology
Targeting EZH2 to treat ETP-ALL
MDedge Hematology and Oncology
Risk of reproductive problems in male cancer survivors
MDedge Hematology and Oncology
Pinpointing the cells that cause CML relapse
MDedge Hematology and Oncology
Drug shows promise for treating resistant AML, MCL
MDedge Hematology and Oncology
Gene variants linked to drug intolerance
MDedge Hematology and Oncology
Chemo linked to long-term learning problems in ALL survivors
MDedge Hematology and Oncology